Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3Gastrointestinal 3Thoracic 2Gynecologic 2Genitourinary 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 38Melanoma 15Neoplasm Metastasis 12Squamous Cell Carcinoma of Head and Neck 11Lung Neoplasms 11Skin Neoplasms 10Neoplasms 9Ovarian Neoplasms 8Recurrence 7Colorectal Neoplasms 7Carcinoma, Renal Cell 7Urinary Bladder Neoplasms 6Head and Neck Neoplasms 6Carcinoma, Basal Cell 6Breast Neoplasms 6Adenocarcinoma 6Uterine Cervical Neoplasms 5Triple Negative Breast Neoplasms 5Colonic Neoplasms 5Carcinoma, Squamous Cell 5Carcinoma, Merkel Cell 5Carcinoma 5Prostatic Neoplasms 4Pancreatic Neoplasms 4Mouth Neoplasms 4Glioblastoma 4Fallopian Tube Neoplasms 4Stomach Neoplasms 3Sarcoma 3Mycosis Fungoides 3

Interventions

Bevacizumab 69atezolizumab 54durvalumab 43lenvatinib 42Nivolumab 38pembrolizumab 35tremelimumab 29Magnetic Resonance Spectroscopy 21Specimen Handling 19tislelizumab 18sintilimab 17Ipilimumab 15Sorafenib 14regorafenib 13cabozantinib 13Radiosurgery 13Radiotherapy 12apatinib 11Blood Specimen Collection 11Immunoglobulin G 10camrelizumab 9Immune Checkpoint Inhibitors 9Disulfides 9X-Rays 8Cyclophosphamide 8donafenib 7Oxaliplatin 7Immunotherapy 7Folfox protocol 7Fluorouracil 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × cemiplimab × 1 year × Clear all
NCT03916627 2026-04-06

Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients

Regeneron Pharmaceuticals

Phase 2 Active not recruiting
65 enrolled
GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular

NCT06923761 2026-01-28

EMITT-1

Grey Wolf Therapeutics

Phase 1/2 Recruiting
300 enrolled
GastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Lung Neoplasms, Neoplasms

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

University of Pittsburgh

Phase 3 Completed
161 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡